Monopar Therapeutics (MNPR)
(Real Time Quote from BATS)
$5.13 USD
-0.26 (-4.82%)
Updated Oct 15, 2024 12:06 PM ET
3-Hold of 5 3
D Value C Growth F Momentum F VGM
Cash flow Statements
Fiscal Year End for Monopar Therapeutics Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -8.40 | -10.52 | -9.10 | -6.30 | -4.22 |
Depreciation/Amortization & Depletion | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change from Assets/Liabilities | -1.35 | 1.65 | 0.32 | 0.44 | 0.19 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 1.90 | 1.64 | 1.47 | 1.20 | 1.01 |
Net Cash From Operating Activities | -7.86 | -7.23 | -7.32 | -4.66 | -3.02 |
Property & Equipment | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 4.93 | -4.92 | 0.00 | 0.00 | 0.00 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | 4.93 | -4.92 | 0.00 | 0.00 | 0.00 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 2.07 | 0.11 | 10.94 | 8.18 | 10.33 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.12 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | -0.05 | -0.08 | -0.06 | -0.12 | -0.97 |
Net Cash from Financing Activities | 2.03 | 0.03 | 10.88 | 8.18 | 9.35 |
Effect of Exchange Rate Changes | -0.02 | 0.00 | 0.00 | 0.00 | -0.01 |
Net Change In Cash & Equivalents | -0.92 | -12.12 | 3.57 | 3.52 | 6.32 |
Cash at Beginning of Period | 8.19 | 20.30 | 16.74 | 13.21 | 6.89 |
Cash at End of Period | 7.27 | 8.19 | 20.30 | 16.74 | 13.21 |
Diluted Net EPS | -3.05 | -4.15 | -3.65 | -2.90 | -2.25 |
Fiscal Year End for Monopar Therapeutics Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | NA | -3.36 | -1.64 | -8.40 | -6.59 |
Depreciation/Amortization & Depletion | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change from Assets/Liabilities | NA | -0.64 | -0.34 | -1.35 | -1.15 |
Net Cash from Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | NA | 0.66 | 0.33 | 1.90 | 1.42 |
Net Cash From Operating Activities | NA | -3.33 | -1.66 | -7.86 | -6.31 |
Property & Equipment | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Acquisition/ Disposition of Subsidiaries | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | NA | -0.99 | -0.98 | 4.93 | 1.96 |
Other Investing Activities | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | NA | -0.99 | -0.98 | 4.93 | 1.96 |
Uses of Funds
9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | NA | 3.19 | 3.19 | 2.07 | 1.73 |
Issuance (Repayment) of Debt | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | NA | -0.02 | -0.01 | -0.05 | -0.04 |
Net Cash from Financing Activities | NA | 3.17 | 3.18 | 2.03 | 1.69 |
Effect of Exchange Rate Changes | NA | 0.00 | 0.00 | -0.02 | -0.01 |
Net Change In Cash & Equivalents | NA | -1.15 | 0.54 | -0.92 | -2.67 |
Cash at Beginning of Period | NA | 7.27 | 7.27 | 8.19 | 8.19 |
Cash at End of Period | NA | 6.12 | 7.81 | 7.27 | 5.52 |
Diluted Net EPS | NA | -0.50 | -0.50 | -0.60 | -0.70 |